grey arrow to go to previous Omnicell webpage or forward to next Omnicell pageBack to Press Release

September 18, 2018

Middlesex Hospital Bolsters Pharmacy Safety and Compliance by Extending Wolters Kluwer's Simplifi 797 with Omnicell's IVX Workflow

Download PDF
Hospital Selects Combined Solution for End-to-End Compliance and Workflow

MOUNTAIN VIEW, Calif., Sept. 18, 2018 /PRNewswire/ -- Wolters Kluwer, Health and Omnicell, Inc. (NASDAQ: OMCL) today announced that Connecticut-based Middlesex Hospital has extended its use of Simplifi 797® and has chosen Omnicell's IVX Workflow to automate the hospital's sterile compounding operations.

The companies provide a turnkey solution that combines the expertise and best-practice approach of quality management solution Simplifi 797 with the advanced IVX Workflow technology from Omnicell. Pharmacies can now leverage an integrated solution with powerful capabilities to improve safety, accuracy and compliance with USP <797> and USP <800> quality standards, which oversee sterile compounding practices in pharmacies.

Scrutiny of compounding policies followed a high-profile meningitis outbreak in 2012 that brought to light weaknesses in the state-level oversight of these potentially risky drugs and the contamination-prone environments where they are formulated. The Pew Charitable Trusts' drug safety project has identified more than 71 reported compounding errors or potential errors from 2001 to 2017 linked to 1,416 adverse events and 115 deaths.

"While states boards have strengthened oversight over the last few years, pharmacies are still playing catch-up in streamlining their compounding processes, as well as in the education and training of pharmacy staff," explained Karen Kobelski, General Manager of Safety and Surveillance at Wolters Kluwer, Health. She adds, "Many pharmacies have yet to tackle the effective management of sterile IV compounding, one of the riskiest aspects of pharmacy operations and one which remains largely untouched by advanced automation."

Middlesex Hospital Automates IV Workflow
Middlesex Hospital is a nearly 300-bed non-profit, acute care community hospital in Middletown, Connecticut. Part of the Mayo Clinic Care Network, Middlesex specializes in oncology, orthopedic services, minimally invasive surgery procedures, bariatric surgery as well as pregnancy and birth services.

Middlesex selected the combined solution to extend the capabilities it already had through Simplifi 797 for nearly three years. Middlesex Hospital had been searching for an IV workflow product for some time, evaluating the design and benefits of available products.

"The IVX Workflow solution really stood out because it was designed to be in an IV clean room right from the start. The solution has a strong combination of software and hardware making it one of the more advanced products we evaluated," explained Anne Marie Calamari, Middlesex Hospital's Director of Pharmacy. "Having Simplifi 797 with the new IVX Workflow solution gives us more assurance on patient safety. And as an existing Simplifi 797 client, there is a comfort level using a solution we know while having access to the new cleanroom features."

About Wolters Kluwer
Wolters Kluwer N.V. is a global provider of professional information, software solutions, and services for physicians, nurses, accountants, lawyers, tax specialists, and finance, audit, compliance, and regulatory sectors.

The company provides expert solutions - a combination of deep domain knowledge with specialized technology and services - that help professionals navigate change, solve complex problems, and deliver impact in their respective fields.

Headquartered in Alphen aan den Rijn, the Netherlands, Wolters Kluwer holds market-leading positions in 40 countries globally, represents customers across 180 countries and employs 19,000 people worldwide. In 2017, it reported annual revenues of €4.4 billion.

Wolters Kluwer is a leading global provider of trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit, follow us on Twitter, Facebook, LinkedIn, and YouTube.

About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been inspired to create safer and more efficient ways to manage medications and supplies across all care settings. Omnicell is revolutionizing the patient medication experience from hospital to home by empowering providers to keep each patient at the center of care. The Company's autonomous approach to medication management leverages a differentiated platform for hardware and workflow software solutions, real-time predictive intelligence, and performance-driven partnerships to help drive operational, financial, and clinical success for customers.

Supporting the highest level of patient safety is essential to excellent patient care. As a leader in medication and supply dispensing automation, central pharmacy automation, IV robotics, analytics software, and medication adherence and packaging systems, Omnicell is focused on delivering solutions for medication availability, affordability, safety, and adherence. Over 4,500 facilities worldwide use Omnicell® automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety.

Omnicell's innovative medication adherence solutions, used by over 32,000 institutional and retail pharmacies in North America and the United Kingdom, are designed to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions.

For more information about Omnicell, Inc. please visit


Editor's Notes:

  1. All Omnicell news releases (financial, acquisitions, products, technology etc.) are issued exclusively by PR Newswire and are immediately thereafter posted on the company's external website,
  2. Omnicell and the Omnicell logo design are registered trademarks of Omnicell, Inc.
  3. All other brand or product names may be trademarks or registered trademarks of their respective companies.


Omnicell, Inc. logo. (PRNewsFoto/Omnicell, Inc.) (PRNewsfoto/Omnicell, Inc.)

Cision View original content to download multimedia:

SOURCE Omnicell, Inc.

Betsy Martinelli, Omnicell, Inc., (724) 741-8341,; or Jessika Parry, Next Step Communications, (781) 326-1741,